Literature DB >> 7259938

Kinetics of intravenous pyridostigmine in man.

T N Calvey, K Chan, A Dehghan, N E Williams.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7259938      PMCID: PMC1401672          DOI: 10.1111/j.1365-2125.1981.tb01146.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  Pharmacokinetics and pharmacological effects of neostigmine in man.

Authors:  T N Calvey; M Wareing; N E Williams; K Chan
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

2.  Pyridostigmine metabolism in man.

Authors:  S M Somani; J B Roberts; A Wilson
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

3.  Comparative times to peak effect and durations of action of neostigmine and pyridostigmine.

Authors:  R D Miller; L S Van Nyhuis; E I Eger; T S Vitez; W L Way
Journal:  Anesthesiology       Date:  1974-07       Impact factor: 7.892

4.  Pyridostigmin (mestinon) as an antagonist of d-tubocurarine.

Authors:  R L Katz
Journal:  Anesthesiology       Date:  1967 May-Jun       Impact factor: 7.892

5.  A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasma.

Authors:  K Chan; N E Williams; J D Baty; T N Calvey
Journal:  J Chromatogr       Date:  1976-05-26

6.  Plasma clearance of neostigmine and pyridostigmine in the dog.

Authors:  P R Baker; T N Calvey; K Chan; C M Macnee; K Taylor
Journal:  Br J Pharmacol       Date:  1978-07       Impact factor: 8.739

  6 in total
  2 in total

Review 1.  Clinical pharmacokinetics of cholinesterase inhibitors.

Authors:  S M Aquilonius; P Hartvig
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Assessment of neuromuscular blockade by electromyography: a review.

Authors:  T N Calvey
Journal:  J R Soc Med       Date:  1984-01       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.